Actuate Therapeutics announced today the pricing of its initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the "Offering").
In addition, the Company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares representing 15% of the shares sold in this offering, solely to cover over-allotments, if any, less the underwriting discount. All of the shares are being offered by the Company.
The shares are expected to begin trading on the Nasdaq Global Market tomorrow, August 13, 2024, under the symbol "ACTU." The Offering is expected to close on August 14, 2024, subject to the satisfaction of customary closing conditions.